BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 28668436)

  • 1. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
    Benndorf M; Hahn F; Krönig M; Jilg CA; Krauss T; Langer M; Dovi-Akué P
    Eur J Radiol; 2017 Aug; 93():9-15. PubMed ID: 28668436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral zone lesions of intermediary risk in multiparametric prostate MRI: Frequency and validation of the PI-RADSv2 risk stratification algorithm based on focal contrast enhancement.
    Benndorf M; Waibel L; Krönig M; Jilg CA; Langer M; Krauss T
    Eur J Radiol; 2018 Feb; 99():62-67. PubMed ID: 29362152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra- and interreader reproducibility of PI-RADSv2: A multireader study.
    Smith CP; Harmon SA; Barrett T; Bittencourt LK; Law YM; Shebel H; An JY; Czarniecki M; Mehralivand S; Coskun M; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2019 Jun; 49(6):1694-1703. PubMed ID: 30575184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.
    Gaur S; Harmon S; Rosenblum L; Greer MD; Mehralivand S; Coskun M; Merino MJ; Wood BJ; Shih JH; Pinto PA; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2018 Jul; 211(1):W33-W41. PubMed ID: 29733695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
    Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
    Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
    In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer.
    Rudolph MM; Baur ADJ; Haas M; Cash H; Miller K; Mahjoub S; Hartenstein A; Kaufmann D; Rotzinger R; Lee CH; Asbach P; Hamm B; Penzkofer T
    Eur Radiol; 2020 Aug; 30(8):4262-4271. PubMed ID: 32219507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
    Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
    AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
    [No Abstract]   [Full Text] [Related]  

  • 10. Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate.
    Purysko AS; Bittencourt LK; Bullen JA; Mostardeiro TR; Herts BR; Klein EA
    AJR Am J Roentgenol; 2017 Aug; 209(2):339-349. PubMed ID: 28570099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interreader Agreement of Prostate Imaging Reporting and Data System Version 2 Using an In-Bore MRI-Guided Prostate Biopsy Cohort: A Single Institution's Initial Experience.
    Glazer DI; Mayo-Smith WW; Sainani NI; Sadow CA; Vangel MG; Tempany CM; Dunne RM
    AJR Am J Roentgenol; 2017 Sep; 209(3):W145-W151. PubMed ID: 28657843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
    Gaur S; Harmon S; Gupta RT; Margolis DJ; Lay N; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
    Acad Radiol; 2019 Jan; 26(1):5-14. PubMed ID: 29705281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions.
    Polanec SH; Helbich TH; Bickel H; Wengert GJ; Pinker K; Spick C; Clauser P; Susani M; Shariat S; Baltzer PAT
    Invest Radiol; 2018 Dec; 53(12):736-741. PubMed ID: 29985792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 17. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
    De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
    Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
    Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA
    Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.
    Hassanzadeh E; Alessandrino F; Olubiyi OI; Glazer DI; Mulkern RV; Fedorov A; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2018 May; 43(5):1237-1244. PubMed ID: 28840280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI-RADS version 2: Preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer.
    Park SY; Shin SJ; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ; Oh YT
    Eur J Radiol; 2017 Jun; 91():22-28. PubMed ID: 28629566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.